Gazeta Wrocławska wrote about us: „Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals.
The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug market for atopic dermatitis in dogs. The value of this market in 2019 was estimated at approximately USD 900 million. However, it can be expected that this value is underestimated – the two most important atopy products from the portfolio of the veterinary giant – Zoetis, i.e. Cytopoint and Apoquel, generated a combined revenue of over $ 700 million in 2019.
Everything indicates that the drug market for atopic dermatitis in dogs, as in humans, will develop dynamically, as the problem of atopy continues to worsen. This is due to the increasing number of allergens in the air and in the food of our pets. „
More on the portal: https://www.wroclaw.pl/biznes/bioceltix-leki-biologiczne